The AJMC® Leukemia & Lymphoma compendium is a comprehensive resource for clinical news and expert insights for the blood cancers and their treatments.
Diet, Exercise Enhance Effects of Chemotherapy, Odds of Survival for Youth With ALL
April 9th 2021Patients who cut their calorie intake by at least 10% and exercised modestly were 70% less likely to have remaining leukemic cells in their bone marrow 1 month after starting chemotherapy, according to results of an early study.
Read More
Emerging Options May Help Address Challenges With Traditional BTK-Inhibitor Treatment in Lymphomas
April 3rd 2021Reversible Bruton tyrosine kinase (BTK) inhibitors may play a key role in treatment when it comes to addressing resistance stemming mutations in the active site (Cys481) that emerge from treatment with irreversible BTK inhibitors.
Read More
Differentiating Between MCL, DLBCL May Require Additional Testing, Case Study Says
April 3rd 2021Classical mantle cell lymphoma (MCL) and 2 aggressive variants exhibited similar rates of negativity for the CD5 marker, but further testing may be needed in certain cases to avoid misdiagnosis with diffuse large B-cell lymphoma (DLBCL).
Read More
Reasons for COVID-19 Vaccine Hesitancy in Patients With Blood Cancer Are Complex
March 19th 2021A survey released this month of US patients with blood cancers shows a somewhat surprising level of hesitancy about receiving a COVID-19 vaccine, but because patients with cancer were not included in clinical trials, the situation for this population is somewhat nuanced.
Read More
Allo-SCT, MRD Negativity Associated With Better Outcomes in AML With Certain Mutations
March 15th 2021Study findings shed a light on the role of minimal residual disease (MRD) status and type of postremission therapy in the prognosis of patients with intermediate-risk acute myeloid leukemia (AML) who do not have FLT3-ITD, NPM1, and biallelic CEBPA mutations.
Read More
Interview: Tanya Siddiqi, MD, Discusses the Promise of Reduced Toxicity With Liso-Cel
February 16th 2021Tanya Siddiqi, MD, director of the chronic lymphocytic leukemia program at Toni Stephenson Lymphoma Center provides insights on what the arrival of liso-cel could mean in the treatment landscape.
Read More
Azacitidine Is Shown to Improve Overall, Relapse-Free Survival in Older Adults With AML
February 15th 2021Older adults with acute myeloid leukemia (AML) saw increased overall and relapse-free survival, as well as preserved quality of life, following oral administration of 300-mg azacitidine.
Read More
TKI Discontinuation Found to Benefit PROs in CML, Study Says
February 6th 2021Results from a new clinical trial suggest that discontinuation of tyrosine kinase inhibitors (TKIs) is safe, feasible and is associated with improvements in patient-related outcomes (PROs) in chronic myeloid leukemia (CML).
Read More
Likely Determinants of Successful TKI Treatment Stoppage Identified in CML
January 16th 2021Tyrosine kinase inhibitor (TKI) therapy enables patients with chronic myeloid leukemia (CML) to reach life expectancies equivalent to the general population and treatment-free remission, but quality of life can deteriorate with treatment.
Read More
Possible New Association Found Between MRD and PFS, OS Among Patients With Mantle Cell Lymphoma
January 7th 2021A recent meta-analysis appearing in Journal of Cancer indicates a connection between minimal residual disease (MRD)–positive status and worse progression-free survival (PFS) and overall survival (OS) following induction and consolidation therapies.
Read More
Small Study Shows Ruxolitinib Helps Severe Steroid-Refractory CRS in Patients With B-ALL
December 30th 2020A small pilot study could point the way to a new option for patients with B-cell acute lymphoblastic leukemia (B-ALL) who experience cytokine release syndrome (CRS) that cannot be cured with the standard therapy.
Read More